drugset / Trial / NCT00112294
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.
Timeline
- Start
- 2004-12
- Primary completion
- 2007-04
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | — |
| Comparator | Paclitaxel | Small molecule | 225 mg/m2 | — |